Summary
This prediction ended on 16.10.17 with a price of €18.28. The prediction had a final performance of 13.79%. melinda has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Ablynx NV | - | - | - | - |
| iShares Core DAX® | 1.014% | 2.699% | 4.363% | 51.689% |
| iShares Nasdaq 100 | -6.470% | -8.771% | 18.004% | 67.992% |
| iShares Nikkei 225® | -6.517% | -12.580% | 40.915% | 57.109% |
| iShares S&P 500 | -2.721% | -1.752% | 16.966% | 58.872% |
Comments by melinda for this prediction
In the thread Ablynx NV diskutieren
Ablynx ( ABLYF.PK ) Montag angekündigt , positive Ergebnisse auf die Grundlinie der Studie der Phase III mit HERCULES caplacizumab, Purpura zur Behandlung von thromboembolischen thrombactique thromboembolischen oder thrombotischen ATTP entwickelt.